/PRNewswire/ Sensible Biotechnologies, Inc., an mRNA platform company, has announced a $4.2mn pre-seed round to accelerate the development of its cell-based.
Panel discussions and interactive workstreams to provide attendees critical insights on evolving regulatory reporting, risk, and finance challenges
. | October 4, 2022
bit.bio’s New Huntington’s Disease Human Cell Model Set to Accelerate Drug Discovery and Screening - read this article along with other careers information, tips and advice on BioSpace
Funding will accelerate clinical development of cell therapies using breakthrough gene engineering technology opti-oxTM Human cell coding company bit.bio today announces the first close of their Series